VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	241M 209M 198M 179M 336M 23.15B 338M 2.36B 912M 11.74B 907M 887M 37.43B	P/E 2026 *	-14.6x	P/E 2027 *	-12.9x
Enterprise Value	241M 209M 198M 179M 336M 23.15B 338M 2.36B 912M 11.74B 907M 887M 37.43B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

15/09	Yarrow Bioscience Closes $172.5 Million Public Offering	MT
11/09	Yarrow Bioscience Launches Public Offering of Common Stock	MT
14/08	Yarrow Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	RTW Biotech's Avere to go public in US in reverse merger with NextCure	AN
03/08	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
29/07	RTW Biotech's Portfolio Company Completes Merger with Vyne Therapeutics	MT
28/07	Yarrow Bioscience, Inc.(NasdaqCM:YARW) added to NASDAQ Composite Index	CI
28/07	Yarrow Bioscience, Inc. completed the acquisition of VYNE Therapeutics Inc. from AI Biotechnology LLC, Nantahala Capital Management LLC, and other shareholders in a reverse merger transaction.	CI
27/07	Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101	MT
27/07	Yarrow Bioscience, Inc. announced that it has received $200 million in funding from a group of investors	CI
24/07	Top Premarket Decliners	MT
21/07	VYNE Approves 1-for-50 Reverse Stock Split	MT
11/07	VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026	CI

03/08	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
31/07/25	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
19/11/24	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
13/05/23	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT
15/03/23	HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	MT

15/09	Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	BU
11/09	Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering	BU
11/09	Yarrow Bioscience Announces Proposed Underwritten Public Offering	BU
13/08	Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update	BU
24/07	VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FOAMIX PHARMACEUTICALS LTD.	-.--%	-16.94%	-	-	19.05M
WUXI APPTEC CO., LTD.	+1.76%	+3.62%	+49.92%	+101.12%	69.69B
ARGENX SE	+1.84%	+0.98%	+37.79%	+77.02%	61.24B
INSMED INCORPORATED	+0.87%	-3.05%	-14.77%	+364.78%	26.77B
WUXI BIOLOGICS (CAYMAN) INC.	+0.32%	+2.58%	+29.26%	+14.12%	26.12B
BIONTECH SE	+2.98%	+2.46%	+0.63%	-9.42%	24.07B
GENMAB A/S	+1.49%	+7.73%	+26.85%	-13.79%	20.39B
PHARMAESSENTIA CORPORATION	-0.83%	-11.15%	+169.70%	+295.44%	15.72B
EXELIXIS, INC.	+2.22%	+0.90%	+43.29%	+171.41%	14.07B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.17%	-4.07%	-9.71%	+484.05%	14.03B
Average	+1.10%	-1.18%	+37.00%	+164.97%	30.23B
Weighted average by Cap.	+1.45%	+0.20%	+36.25%	+129.50%

Foamix Pharmaceuticals Ltd. Stock Nasdaq

Stocks

IL0011334385

Biotechnology & Medical Research

Valuation: Foamix Pharmaceuticals Ltd.

Latest news: Foamix Pharmaceuticals Ltd.

Last Transcript: Foamix Pharmaceuticals Ltd.

Analysts' recommendations: Foamix Pharmaceuticals Ltd.

Press Releases: Foamix Pharmaceuticals Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

	2026 *	2027 *
Net sales	-	-
Net income	-38.54M -33.4M -31.57M -28.66M -53.72M -3.7B -54.04M -377M -146M -1.88B -145M -142M -5.98B	-66.89M -57.97M -54.79M -49.74M -93.23M -6.42B -93.79M -654M -253M -3.25B -251M -246M -10.38B
Net Debt	-	-